Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study

Haematologica

Volumn 89, Issue 10, 2004, Pages 1275-1276

  Lefrere, François ^a   Delmer, Alain ^b   Levy, Vincent ^c   Delarue, Richard ^a   Varet, Bruno ^a   Hermine, Olivier ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔTEL DIEU   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Autograft; CHOP; DHAP; Mantle cell lymphoma; TBI

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; MITOXANTRONE;

ADULT; ARTICLE; AUTOGRAFT; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FOLLOW UP; HUMAN; LONG TERM CARE; MANTLE CELL LYMPHOMA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SEQUENTIAL CHEMOTHERAPY; SEQUENTIAL INJECTION ANALYSIS; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; LIFE TABLES; LYMPHOMA, MANTLE-CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE; WHOLE-BODY IRRADIATION;

EID: 6344237738     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognosis factors. Cancer 1998;82:567-75.
2. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, Vaughan Hudson B, Pittaluga S, Anderson L, et al. The clinical outcome of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99:842-7.
3. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281-7.
4. Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan RC. CDs-expressing B cell non Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995;85:1570-9.
5. Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587-93.
6. Khouri I, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803-9.
7. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000;39:77-85.
8. Seymour JF, Grigg AP, Szer J, Fox RM. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, historically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002;94:585-93.
9. Zinzani PL, Magagnoli M, Moretti L, Battista R, Ronconi F, De Renzo A, et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica 1999;84:1002-6.
10. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004;83:71-7.